What is tirzepatide mixed with, and does the formulation matter?

What inactive ingredients is tirzepatide formulated with?

Each pre-filled Mounjaro KwikPen contains tirzepatide dissolved in a clear, colourless to slightly yellow aqueous solution. Alongside the active ingredient, the formulation listed in the Summary of Product Characteristics (SmPC) on the Electronic Medicines Compendium includes sodium phosphate dibasic heptahydrate and sodium phosphate monobasic monohydrate, two forms of phosphate salt that together act as a buffer, keeping the solution's pH stable during storage and making the injection less irritating at the site. You will also find mannitol, a sugar alcohol that helps maintain the solution's osmotic balance and adds to its stability. Phenol is present as a preservative, which is standard in multi-dose injectable medicines and keeps the solution sterile across the four weekly injections a single pen contains. Finally, water for injections makes up the solvent base.

None of these excipients are therapeutic, they do not lower blood sugar or reduce appetite. Their job is to keep the tirzepatide molecule intact and effective from the day the pen is filled at the manufacturing site to the moment you use the last dose. If you have a known allergy to any of these components, that is something to raise during your clinical consultation, because the prescriber needs to know before approving treatment. If you are curious about what tirzepatide is made of, including both its active structure and the inactive components that support it, our dedicated page covers this in detail. You can also read the complete excipient list in the Mounjaro SmPC on the Electronic Medicines Compendium, which also covers storage conditions and handling instructions.

Is anything added or mixed by the pharmacist before it is sent out?

No. This is a question our prescribers hear most weeks, and it is worth being direct: the solution inside the pen is manufactured under pharmaceutical conditions by Eli Lilly and arrives fully formulated. GPhC-registered pharmacies like ours do not open, dilute, reconstitute or add anything to the pen before dispatch. What comes off the licensed supply chain is what reaches you.

This matters more than it might seem. A number of counterfeit weight-loss pens circulating outside the licensed UK supply chain have contained unlabelled substances, including insulin in some cases documented by the MHRA. The only guarantee that a pen's contents match its label is sourcing through a pharmacy you can verify on the GPhC register. The pen you receive from a verified pharmacy is sealed and tamper-evident; if the packaging has been interfered with, do not use it and contact the pharmacy immediately.

For more context on how the medicine itself works, our page explaining what tirzepatide is covers the science without the jargon.

Does the formulation affect how tirzepatide is stored or used?

The presence of phenol and phosphate buffers means the solution needs to be kept refrigerated between 2°C and 8°C to maintain potency and sterility. There is a defined window during which the pen may be kept at room temperature, but the exact duration is specified in the Patient Information Leaflet rather than here, always check the leaflet that comes with your pen, because the window differs by storage history and the SmPC is the authoritative source. Keep the pen in its outer carton to protect it from light.

The pen itself is a pre-set auto-injector. There is no plunger to depress manually, no needle to attach for injection (the needle is integrated) and no dial to set. You select the injection site (abdomen, thigh or upper arm) clean the skin, press the pen against it and release. Rotating sites prevents localised tissue changes over time. If you want a broader picture of what tirzepatide are and what the medicine is designed to do once injected, our guide to what tirzepatide helps with explains the clinical outcomes in plain terms.

Storage and handling questions that go beyond the leaflet (say, whether a pen that was left out overnight is still usable) should go to your prescribing team or the pharmacist, not a general search. At nume, aftercare support is available seven days a week for exactly this kind of practical question; you can reach us through our contact page.

Could any ingredient in the formulation interact with other medicines?

The excipients themselves are not known to cause clinically relevant interactions. The interaction picture for tirzepatide relates to the active molecule and its mechanism rather than the inactive ingredients. Because tirzepatide slows gastric emptying, it can delay the absorption of other oral medicines taken at the same time, affecting how quickly they reach therapeutic levels in the blood. This is particularly relevant for oral contraceptives, where the guidance is to use a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, as noted in NHS guidance on tirzepatide.

The wider list of medicines to discuss before starting tirzepatide (including diabetes medicines that carry a low blood sugar risk, thyroid medicines and others with narrow therapeutic windows) is covered separately on the page on what not to take with tirzepatide. Bring a full list of your current medicines to the consultation; the prescriber works through it as part of the clinical review. You can find out more about the clinical team behind that review on our clinical team page.

If you are considering treatment and want to understand whether tirzepatide is likely to suit your situation, you can read more on our tirzepatide information page before taking the next step. Start your free consultation and a GPhC-registered Independent Prescriber will review your details the same day.